Saturday 17 October 2026 Export XBIT’s income statement to Excel — free account

XBiotech Inc.

XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.

2.12 0.04 −1.85%

Follow XBIT

Alert me

Market cap: $65.9M
P/E: 0.0×
Fwd P/E: −3.3×
Dividend yield: —
F-score: 3/9
Altman Z: 11.69
Beneish M: −4.17
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 36.86%

Capital & Financial Ratios $m

Market Cap 65.85

Revenue 4.01

Net Income (45.13)

Free Cash Flow (40.69)

Net Debt (109.53)

Current Ratio 33.15

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.25)

P/S ratio 16.12

P/B ratio 0.50

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (100.00%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.27%

10-year low 10-year high

P/B against its own 10 years 10.87%

10-year low 10-year high

EV/FCF against its own 10 years 19.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	2.10	2.10
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	200	173	126	110
Receivables	1	1	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	202	175	127	111

	2023	2024	2025	Q'26
Payables	3	2	2	1
ST’ Debt	—	10	—	—
Other	—	—	—	—
	6	15	8	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	3.14%	(16.64%)	(16.42%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	1	2	2	0	4
’21	5	5	5	5	18

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(5)	—	—	—
’25	(7)	(6)	(4)	(23)	(40)
’24	(7)	(11)	(6)	(7)	(31)
’23	(5)	(9)	(1)	(3)	(19)
’22	(5)	(5)	(1)	(3)	(15)
’21	2	73	(3)	(2)	69
’20	(61)	(12)	7	0	(65)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(5)	—	—	—
’25	(7)	(6)	(4)	(23)	(40)
’24	(7)	(12)	(6)	(7)	(32)
’23	(5)	(9)	(2)	(4)	(19)
’22	(5)	(5)	(1)	(3)	(15)
’21	1	71	(4)	(2)	66
’20	(61)	(12)	7	(3)	(69)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	(0.22)	—	—	—
’25	(0.36)	(0.06)	(0.20)	(0.88)	(1.49)
’24	(0.33)	(0.43)	(0.16)	(0.34)	(1.26)
’23	(0.13)	(0.29)	(0.24)	(0.16)	(0.81)
’22	(0.18)	(0.38)	(0.42)	(0.10)	(1.08)
’21	(0.09)	(0.17)	(0.11)	(0.21)	(0.58)
’20	0.00	(0.24)	(0.09)	(0.06)	(0.36)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.36	2.77	2.13	4.78	8.72	10.71	3.00	3.05	3.51	2.09	Analyst estimates 2026–2028 Powerpack
	High	25.00	20.18	6.50	22.95	26.40	20.75	11.90	6.69	9.96	4.67
People
People	Employees	106	51	56	49	91	97	85	82	92	85
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.48	0.19	0.05	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	44	18	4	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	21.48	68.36	83.77	—	—	—
	EBT	(53)	(33)	(21)	718	(13)	(25)	(34)	(24)	(39)	(45)
	EBT margin, %	0.00	0.00	0.00	0.00	(29.15)	(138.40)	(837.61)	0.00	0.00	0.00
	Net income	(53)	(33)	(21)	669	(11)	(17)	(33)	(25)	(39)	(46)
	Depreciation	1	1	2	2	2	3	3	2	2	2
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	1.43	0.61	0.13	0.00	0.00	0.00
	Earnings	(1.63)	(0.95)	(0.59)	17.17	(0.36)	(0.58)	(1.08)	(0.81)	(1.26)	(1.49)
	Cash flow	(1.42)	(0.96)	(0.46)	(0.47)	(2.11)	2.31	(0.49)	(0.62)	(1.02)	(1.31)
	Capex	(0.43)	(0.04)	0.00	(0.01)	(0.12)	(0.12)	(0.02)	(0.01)	(0.04)	(0.01)
	Free cash flow	(1.85)	(1.01)	(0.47)	(0.47)	(2.23)	2.19	(0.51)	(0.63)	(1.06)	(1.32)
	Book value	1.82	1.73	1.16	19.40	11.31	8.97	7.90	7.19	5.98	4.60
	Shares, m	32	35	36	39	31	30	30	30	30	30
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	—	—	—
	P/S	—	—	—	—	10.96	18.18	25.66	—	—	—
	P/B	—	—	—	—	1.38	1.24	0.43	—	—	—
	EV/Sales	—	—	—	—	5.57	5.30	(28.58)	—	—	—
	EV/FCF	—	—	—	—	(3.56)	1.48	7.44	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(46)	(34)	(17)	(18)	(65)	69	(15)	(19)	(31)	(40)
	Capex	(14)	(1)	0	0	(4)	(4)	(1)	0	(1)	0
	Free cash flow	(60)	(35)	(17)	(18)	(69)	66	(15)	(19)	(32)	(40)
Balance, $m
Balance, $m	Working capital	29	31	14	656	322	243	216	196	159	119
	Total debt	—	—	—	—	—	—	—	—	10	—
	Net debt	(34)	(32)	(16)	(715)	(237)	(237)	(217)	(200)	(162)	(126)
	Shareholders’ equity	59	60	41	756	349	269	240	219	182	140
Returns, %
Returns, %	ROA	(59.82)	(50.99)	(39.39)	155.27	(1.92)	(5.54)	(12.62)	(10.39)	(18.10)	(26.08)
	ROIC	(133.29)	(74.97)	(51.30)	(47.57)	(10.27)	(48.38)	(94.03)	(124.55)	(133.79)	(235.17)
	ROE	(65.09)	(55.61)	(41.63)	167.78	(2.03)	(5.64)	(12.91)	(10.69)	(19.21)	(28.23)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSBR Champions Oncology, Inc.	$66.7M	— (loss-making)	— (loss-making)	+8.84% (above 0%: growing)	n/m	−198.74% (below 0%: shrinking)	50.54%	(2.69%)	Compare
OSTX OS Therapies Incorporated	$66.0M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
HYFT MindWalk Holdings Corp.	$66.0M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)	Compare
XBIT XBiotech Inc.	$65.9M	— (loss-making)	— (loss-making)	−93.33% (below 0%: shrinking)	n/m	+25.25% (above 0%: growing)	0.00%	0.00%
NMAD Nomad Power Solutions, Inc.	$65.9M	— (loss-making)	—	—	n/m	−230.63% (below 0%: shrinking)	—	0.00%	Compare
SPRO Spero Therapeutics, Inc.	$65.8M	7.9×	4.2×	−95.61% (below 0%: shrinking)	n/m	+69.73% (above 0%: growing)	100.00%	0.00%	Compare
VRCA Verrica Pharmaceuticals Inc.	$64.9M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)	Compare
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
FBIO Fortress Biotech, Inc.	$63.7M	0.6×	1.1×	+14.04% (above 0%: growing)	n/m	−115.37% (below 0%: shrinking)	67.18%	(53.46%)	Compare
Median of peers	$65.8M	—	—	+8.84%	—	−69.82%	62.88%	(1.34%)

All 614 Biotechnology stocks →

XBiotech Inc. (XBIT) key facts

XBiotech Inc. (XBIT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million.
As of October 16, 2026, XBIT traded at $2.12, a market capitalization of $65.9 million.
Return on equity was −28.2% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 11.69 (safe zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.